a:5:{s:8:"template";s:6603:"<!DOCTYPE html>
<html lang="de">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Droid+Sans%3A400%2C700%7CRoboto+Slab%3A400%2C300%2C700&amp;ver=3.2.4" id="google-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}footer,header,nav{display:block}a{background-color:transparent;-webkit-text-decoration-skip:objects}a:active,a:hover{outline-width:0}::-webkit-input-placeholder{color:inherit;opacity:.54}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}html{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}*,:after,:before{box-sizing:inherit}.nav-secondary:before,.site-container:before,.site-footer:before,.site-header:before,.site-inner:before,.wrap:before{content:" ";display:table}.nav-secondary:after,.site-container:after,.site-footer:after,.site-header:after,.site-inner:after,.wrap:after{clear:both;content:" ";display:table}html{font-size:62.5%}body>div{font-size:1.6rem}body{background-color:#efefe9;color:#767673;font-family:'Droid Sans',sans-serif;font-size:16px;font-size:1.6rem;font-weight:300;line-height:1.625}a{-webkit-transition:all .1s ease-in-out;-moz-transition:all .1s ease-in-out;-ms-transition:all .1s ease-in-out;-o-transition:all .1s ease-in-out;transition:all .1s ease-in-out}::-moz-selection{background-color:#333;color:#fff}::selection{background-color:#333;color:#fff}a{color:#27968b;text-decoration:none}a:focus,a:hover{color:#222;text-decoration:underline;-webkit-text-decoration-style:dotted;text-decoration-style:dotted}p{margin:0 0 16px;padding:0}ul{margin:0;padding:0}::-moz-placeholder{color:#6a6a6a;opacity:1}::-webkit-input-placeholder{color:#6a6a6a}.site-container-wrap{background-color:#fff;box-shadow:0 0 5px #ddd;margin:32px auto;max-width:1140px;overflow:hidden;padding:36px}.site-inner{clear:both;padding-top:32px}.wrap{margin:0 auto;max-width:1140px}:focus{color:#333;outline:#ccc solid 1px}.site-header{background-color:#27968b;padding:48px;overflow:hidden}.title-area{float:left;width:320px}.site-title{font-family:'Roboto Slab',sans-serif;font-size:50px;font-size:5rem;line-height:1;margin:0 0 16px}.site-title a,.site-title a:focus,.site-title a:hover{color:#fff;text-decoration:none}.header-full-width .site-title,.header-full-width .title-area{text-align:center;width:100%}.genesis-nav-menu{clear:both;font-size:14px;font-size:1.4rem;line-height:1;width:100%}.genesis-nav-menu .menu-item{display:block}.genesis-nav-menu>.menu-item{display:inline-block;text-align:left}.genesis-nav-menu a{color:#fff;display:block;padding:20px 24px;position:relative;text-decoration:none}.genesis-nav-menu a:focus,.genesis-nav-menu a:hover{outline-offset:-1px}.genesis-nav-menu a:focus,.genesis-nav-menu a:hover,.genesis-nav-menu li>a:focus,.genesis-nav-menu li>a:hover{background-color:#fff;color:#767673}.genesis-nav-menu .menu-item:hover{position:static}.nav-secondary{background-color:#27968b;color:#fff}.nav-secondary .wrap{background-color:rgba(0,0,0,.05)}.menu .menu-item:focus{position:static}.site-footer{background-color:#27968b;color:#fff;font-size:12px;font-size:1.2rem;padding:36px;text-align:center}.site-footer p{margin-bottom:0}@media only screen and (max-width:1139px){.site-container-wrap,.wrap{max-width:960px}}@media only screen and (max-width:1023px){.site-container-wrap,.wrap{max-width:772px}.title-area{width:100%}.site-header{padding:20px 0}.site-header .title-area{padding:0 20px}.genesis-nav-menu li{float:none}.genesis-nav-menu,.site-footer p,.site-title{text-align:center}.genesis-nav-menu a{padding:20px 16px}.site-footer{padding:20px}}@media only screen and (max-width:767px){body{font-size:14px;font-size:1.4rem}.site-container-wrap{padding:20px 5%;width:94%}.site-title{font-size:32px;font-size:3.2rem}}p.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}p.has-drop-cap:not(:focus):after{content:"";display:table;clear:both;padding-top:14px}/*! This file is auto-generated */@font-face{font-family:'Droid Sans';font-style:normal;font-weight:400;src:local('Droid Sans Regular'),local('DroidSans-Regular'),url(http://fonts.gstatic.com/s/droidsans/v12/SlGVmQWMvZQIdix7AFxXkHNSaA.ttf) format('truetype')}@font-face{font-family:'Droid Sans';font-style:normal;font-weight:700;src:local('Droid Sans Bold'),local('DroidSans-Bold'),url(http://fonts.gstatic.com/s/droidsans/v12/SlGWmQWMvZQIdix7AFxXmMh3eDs1Yg.ttf) format('truetype')}@font-face{font-family:'Roboto Slab';font-style:normal;font-weight:300;src:url(http://fonts.gstatic.com/s/robotoslab/v11/BngbUXZYTXPIvIBgJJSb6s3BzlRRfKOFbvjo0oSmb2Rm.ttf) format('truetype')}@font-face{font-family:'Roboto Slab';font-style:normal;font-weight:400;src:url(http://fonts.gstatic.com/s/robotoslab/v11/BngbUXZYTXPIvIBgJJSb6s3BzlRRfKOFbvjojISmb2Rm.ttf) format('truetype')}@font-face{font-family:'Roboto Slab';font-style:normal;font-weight:700;src:url(http://fonts.gstatic.com/s/robotoslab/v11/BngbUXZYTXPIvIBgJJSb6s3BzlRRfKOFbvjoa4Omb2Rm.ttf) format('truetype')}</style>
</head>
<body class="custom-background header-full-width content-sidebar" itemscope="" itemtype="https://schema.org/WebPage"><div class="site-container"><div class="site-container-wrap"><header class="site-header"><div class="wrap"><div class="title-area"><p class="site-title" itemprop="headline"><a href="#">{{ keyword }}</a></p></div></div></header><nav aria-label="Secondary" class="nav-secondary" id="genesis-nav-secondary"><div class="wrap"><ul class="menu genesis-nav-menu menu-secondary js-superfish" id="menu-main"><li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-55" id="menu-item-55"><a href="#" itemprop="url"><span itemprop="name">Home</span></a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-56" id="menu-item-56"><a href="#" itemprop="url"><span itemprop="name">Curation Policy</span></a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-57" id="menu-item-57"><a href="#" itemprop="url"><span itemprop="name">Privacy</span></a></li>
</ul></div></nav><div class="site-inner">
{{ text }}
<br>
{{ links }}
</div><footer class="site-footer" itemscope="" itemtype="https://schema.org/WPFooter"><div class="wrap"><p>{{ keyword }} 2021</p></div></footer></div></div>
</body></html>";s:4:"text";s:20464:"Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Yahoo 09/08 16:30 ET. Jadeite Medicines is backed by CBC Group (www.cbridgecap.com), who has partnered with the world’s top entrepreneurs and scientists and, leveraging its unique “investor-operator” approach, has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations and improve efficiency in fulfilling unmet medical needs worldwide. Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 09/08 16:30. In 2020, Albireo Pharma&#x27;s revenue was $8.31 million, a decrease of -13.78% compared to the previous year&#x27;s $9.64 million. All rights reserved. Chart represents Albireo Pharma, Inc. price and volume over 1Y period View as data table, Albireo Pharma, Inc. price and volume The chart has 1 X axis . Resume Be sure to include an updated resume. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo&#x27;s common stock and. • Supported the strategic design of a franchise portfolio and led the execution of the HCP . - PRV was granted to Albireo with the FDA approval of Bylvay TM (odevixibat) in July - - Non-dilutive capital further strengthens the Company&#x27;s financial position - BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that it has entered into a definitive agreement . The link you have selected will take you outside of Albireo Pharma&#x27;s corporate website. Please switch to a supported browser listed here, or some . BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), the first drug approved in Europe for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC), is now available by prescription to patients in Germany. Albireo disclaims any obligation to update any forward-looking statement except as required by applicable law. – Bylvay™  (odevixibat) approved in the U.S. and Europe , partial Q3 ’21 revenue of $1.1 million – – ASSERT & BOLD Phase 3 studies enrolling, on track for topline data readouts – – 12 abstracts accepted at AASLD & NASPGHAN scientific congresses – – A3907 Phase 1 topline data expected in Q4’21, — Conference call and webcast to be held at 10:00 a.m. Greater Boston Area. Im Buch gefunden – Seite 296... Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, Abbott Labs, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novonordisk, GSK, ... Bylvay Now Commercially Available in Germany As U.S. BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today . BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today provided a business . Albireo Pharma (ALBO) has an average rating of buy and price targets ranging from $59 to $84, according to analysts polled by Capital IQ. Nachrichten zur Aktie Albireo Pharma Inc Registered Shs | A2DF99 | ALBO | US01345P1066 Albireo disclaims any obligation to update any forward-looking statement except as required by applicable law. Ana wurde durch ihre Eltern HIV-infiziert. Sie durchlebt eine schwierige Kindheit: Sie wird geschlagen und missbraucht. Aber sie findet auch Menschen, die ihr Mut machen und sie bestärken, ihr Leben selbst zu gestalten. Ab 13. EU Product Information All linguistic versions of the EU Product Information for Bylvay can be found here.. UK Product Information. (MT Newswires. BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), the first drug approved in Europe for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC), is now available by prescription to patients in Germany. Im Buch gefunden – Seite 6Its executive chairpatients get better when they pany , Albireo . ... in the case of search projects that the pharma ing in healthcare - Nomura tures that realise the full potenparoxetine , only 16 trials out of a parents did not want ... Albireo Pharma (ALBO) reported a 2nd Quarter June 2021 loss of $1.90 per share on revenue of $2.4 million. About AlbireoAlbireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. The Company received the voucher with the approval of Bylvay for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC). Albireo&#x27;s product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being . The proceeds allow us to continue our mission to ensure that all diagnosed children with PFIC in the U.S. and Europe will have access to Bylvay, progress two additional Bylvay Phase 3 studies and advance two new product candidates,” said Ron Cooper, President and Chief Executive Officer of Albireo. For full prescribing information, visit www.bylvay.com. Im Vorjahresquartal hatten -1,960 USD .  “The sale of the PRV provides Albireo with an important source of non-dilutive capital and further strengthens our balance sheet. For more information about using Bylvay, see the package leaflet or contact your doctor or pharmacist. The ASSERT and BOLD studies remain on track to report topline data in 2022 and 2024 respectively. CBC focuses on platform-building, buyout, credit and growth-focused opportunities across multiple core areas within the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services. Bylvay is being evaluated in the ongoing PEDFIC 2 open-label trial in patients with PFIC, in the BOLD Phase 3 study for patients with biliary atresia and the ASSERT Phase 3 study for Alagille syndrome. Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. The PICTURE Burden of Illness Study: Quantifying the Socio-economic Burden of Progressive Familial Intrahepatic Cholestasis (PFIC) in the US, UK, France and Germany Journal of Pediatric Gastroenterology and Nutrition. Copyright � 2021 Surperformance. To learn more about the program, visit AlbireoAssist.com. Albireo Pharma (ALBO) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of $0.54. Albireo Pharma announces Bylvay now available in Germany 09/08/21 Albireo Pharma receives UK MHRA approval of Bylvay 09/07/21 Albireo Pharma sells priority review voucher for $105M. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. Bylvay does not require refrigeration and can be taken as a capsule for older children, or opened and sprinkled onto food, which are factors of key importance for adherence in a pediatric patient population. Im Buch gefunden – Seite 98Albireo , which was formed by spinning out much of AstraZeneca's gastrointestinal IP assets , is but one example of ... private partnerships will supplement and motivate increased external licensing efforts by pharma companies . Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), the first drug approved in Europe for . - Data show Bylvay therapy up to 128 weeks, sustained improvements in hepatic health, quality of sleep and growth, reducing disease burden - - First data on A2342, the first oral systemic NTCP inhibitor, shows inhibition of Hepatitis B viral entry and replication in preclinical models - - Company to host post-AASLD call on November 16, 2021 at 10 a.m. acted as legal advisor. Albireo Pharma Launches Bylvay in Germany. It engages in the research and development of drug reformulation technology. Financial Statements. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. – Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained improvements in hepatic health, quality of sleep and growth, reducing disease burden – – First data on, BOSTON , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, Simon Harford , Chief Financial Officer and other members of the Company’s. Showing records 1 - 20 ( 292 total ) . Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and . Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, has its first regulatory approval for Bylvay, generically known as odevixibat, a drug . For patients outside the U.S., access to Bylvay in certain countries is now available through our Managed Access Program. – Bylvay now approved in U.S. , EU and UK as first drug treatment for patients with PFIC   – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to date – BOSTON , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Generation Bile Acid Modulator Data at AASLD The Liver Meeting® 2021, Albireo to Present at Upcoming Investor Conferences, Albireo Reports Q3 Financial Results and Business Update, Albireo to Report Third Quarter 2021 Financial Results on November 4, Albireo to Showcase New Data at AASLD The Liver Meeting® 2021, Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan, Albireo Recognizes PFIC Awareness Day 2021, Albireo Announces Bylvay® (odevixibat) Now Available in Germany, Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), Albireo Receives UK MHRA Approval of Bylvay® (odevixibat). “The agreement allows for success of both companies, while strengthening Albireo’s financial position with the $15M payment added to our strong balance sheet.”. BOSTON, Sept.  07, 2021  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) for $105 million. - Listed on the German national price list and all pharmacy software programs - - Bylvay is approved in U.S., EU and UK as first drug treatment for patients with PFIC - - Only once-daily drug indicated to treat all forms of PFIC - BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid . Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver . – PRV was granted to Albireo with the FDA approval of BylvayTM (odevixibat) in July –, – Non-dilutive capital further strengthens the Company’s financial position –. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. ALBIREO PHARMA AKTIE und aktueller Aktienkurs. Please try again later. Boston, sept. 08, 2021 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of albireo&#x27;s common stock and restricted stock units representing the opportunity to acquire 3,500 shares of albireo&#x27;s common stock. Albireo Pharma, Inc. ( ALBO ), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo s common stock and restricted stock units representing the opportunity to acquire 3,500 shares of Albireo s common stock. Im Buch gefunden – Seite 3-196Examples of such transactions include the merger between Tokai Pharmaceuticals, Inc. and Otic Pharma, Ltd. (2017), the merger between Biodel Inc. and Albireo Limited (2016), the merger between Macrocure Ltd. and Leap Therapeutics, ... Albireo disclaims any obligation to update any forward-looking statement except as required by applicable law. Yahoo. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. As of September 30, 2021, we had cash and cash . Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. About Bylvay (odevixibat)Bylvay is the first drug approved in the U.S. for the treatment of pruritus in patients 3 months of age and older in all types of progressive familial intrahepatic cholestasis (PFIC). The European Commission (EC) has also granted marketing authorization of Bylvay for the treatment of PFIC, which will be available for sale in Europe following pricing and reimbursement approval. Im Buch gefunden – Seite 152... Inc. Alba Therapeutics Corporation Albireo Pharma Alfa Wassermann SpA Allozyne, Inc. Altheus Therapeutics, ... SA Daiichi Sankyo Company Ltd. DBV Technologies SA Delenex Therapeutics AG Dr. Falk Pharma GmbH Effimune SAS Eisai Co. In addition, any forward-looking statement in this press release represents Albireo’s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Jul 20, 2021. The European Commission (EC) has approved Albireo Pharma Inc&#x27;s (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC). Im Buch gefunden – Seite 223... Novo Nordisk, Rose Pharma, Prometheus, and Salix; William D. Chey is a consultant for Albireo, Ironwood, Movetis, and Salix. a Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, ... About Albireo Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Bylvay is the first drug approved in Europe for the treatment of all types of PFIC and in the U.S. for the treatment of pruritus in all types of PFIC. BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Bylvay (odevixibat), the first drug approved in Europe for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC), is now available by . In partnering with the world’s top entrepreneurs and scientists, our unique “investor-operator” approach has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. Some better-ranked stocks in the biotech sector include Biomarin Pharmaceutical BMRN and Exact Sciences EXAS, each sporting a Zacks Rank #1 (Strong . For patients in Germany, we also offer . Albireo Pharma announces Bylvay now available in Germany 09/08/21 Albireo Pharma receives UK MHRA approval of Bylvay 09/07/21 Albireo Pharma sells priority review voucher for $105M. 09/15 08:30. Launch Continues to Build Momentum. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including, but not limited to: there are no guarantees that Bylvay will be commercially successful; we may encounter issues, delays or other challenges in launching or commercializing Bylvay; whether Bylvay receives adequate reimbursement from third-party payors; the degree to which Bylvay receives acceptance from patients and physicians for its approved indication; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in Bylvay in the treatment of patients with PFIC may be different than observed in clinical trials, and may vary among patients; other potential negative impacts of the COVID-19 pandemic, including on manufacturing, supply, conduct or initiation of clinical trials, or other aspects of our business; whether favorable findings from clinical trials of Bylvay to date, including findings in indications other than PFIC, will be predictive of results from other clinical trials of Bylvay; the outcome and interpretation by regulatory authorities of the ongoing third-party study pooling and analyzing of long-term PFIC patient data; the timing for initiation or completion of, or for availability of data from, clinical trials of Bylvay, including BOLD and ASSERT, and the Phase 1 clinical trial of A3907, and the outcomes of such trials; Albireo’s ability to obtain coverage, pricing or reimbursement for approved products in the United States or Europe; delays or other challenges in the recruitment of patients for, or the conduct of, Company’s clinical trials; and Albireo’s critical accounting policies. For patients in Germany, we also offer . The next earnings announcement is expected on Mar 02, 2022. Albireo Pharma Inc is a biopharmaceutical company. Albireo&#x27;s first product, Bylvay™ (odevixibat) is the first drug treatment approved in the U.S. for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC). Dr. med. William Davis zeigt glutenfreie Ernährungsalternativen auf, und wie man gesund und schlank ohne Weizen leben kann. Der Weltbestseller komplett überarbeitet und erweitert. – Listed on the German national price list and all pharmacy software programs – – Bylvay is approved in U.S. , EU and UK as first drug treatment for patients with PFIC   – – Only once-daily drug indicated to treat all forms of PFIC – BOSTON , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. BOSTON , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo’s common stock and restricted. ";s:7:"keyword";s:26:"albireo pharma deutschland";s:5:"links";s:1055:"<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=zinsentwicklung-1950-bis-heute">Zinsentwicklung 1950 Bis Heute</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=lehrerfortbildung-bw-biologie">Lehrerfortbildung Bw Biologie</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=iberogast-50-ml-preisvergleich">Iberogast 50 Ml Preisvergleich</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=derivate-deutsch-englisch">Derivate Deutsch Englisch</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=wasen-ersatz-stuttgart">Wasen Ersatz Stuttgart</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=squid-game-spielleiter">Squid Game Spielleiter</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=webbschule-brandenburg">Webbschule Brandenburg</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=leveraged-etf-deutschland">Leveraged Etf Deutschland</a>,
<a href="https://punkpirates.io/of6ep4ti/viewtopic.php?tag=ringmagnet-magnetfeld">Ringmagnet Magnetfeld</a>,
";s:7:"expired";i:-1;}